Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies

Carlotta Nannini, Colin Patrick West, Patricia J. Erwin, Eric Lawrence Matteson

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Introduction: The purpose of the present study was to systematically review the effect of cyclophosphamide treatment on pulmonary function in patients with systemic sclerosis and interstitial lung disease. Methods: The primary outcomes were the mean change in forced vital capacity and in diffusing capacity for carbon monoxide after 12 months of therapy in patients treated with cyclophosphamide. Results: Three randomized clinical trials and six prospective observational studies were included for analysis. In the pooled analysis, the forced vital capacity and the diffusing capacity for carbon monoxide predicted values after 12 months of therapy were essentially unchanged, with mean changes of 2.83% (95% confidence interval = 0.35 to 5.31) and 4.56% (95% confidence interval = -0.21 to 9.33), respectively. Conclusions: Cyclophosphamide treatment in patients with systemic sclerosis-related interstitial lung disease does not result in clinically significant improvement of pulmonary function.

Original languageEnglish (US)
Article numberR124
JournalArthritis Research and Therapy
Volume10
Issue number5
DOIs
StatePublished - Oct 20 2008

Fingerprint

Interstitial Lung Diseases
Cyclophosphamide
Meta-Analysis
Cohort Studies
Randomized Controlled Trials
Prospective Studies
Lung
Systemic Scleroderma
Vital Capacity
Carbon Monoxide
Confidence Intervals
Therapeutics
Observational Studies

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)
  • Immunology and Allergy
  • Rheumatology

Cite this

@article{3f276e945d904af08fc9987bf30cbb68,
title = "Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies",
abstract = "Introduction: The purpose of the present study was to systematically review the effect of cyclophosphamide treatment on pulmonary function in patients with systemic sclerosis and interstitial lung disease. Methods: The primary outcomes were the mean change in forced vital capacity and in diffusing capacity for carbon monoxide after 12 months of therapy in patients treated with cyclophosphamide. Results: Three randomized clinical trials and six prospective observational studies were included for analysis. In the pooled analysis, the forced vital capacity and the diffusing capacity for carbon monoxide predicted values after 12 months of therapy were essentially unchanged, with mean changes of 2.83{\%} (95{\%} confidence interval = 0.35 to 5.31) and 4.56{\%} (95{\%} confidence interval = -0.21 to 9.33), respectively. Conclusions: Cyclophosphamide treatment in patients with systemic sclerosis-related interstitial lung disease does not result in clinically significant improvement of pulmonary function.",
author = "Carlotta Nannini and West, {Colin Patrick} and Erwin, {Patricia J.} and Matteson, {Eric Lawrence}",
year = "2008",
month = "10",
day = "20",
doi = "10.1186/ar2534",
language = "English (US)",
volume = "10",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "5",

}

TY - JOUR

T1 - Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease

T2 - A systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies

AU - Nannini, Carlotta

AU - West, Colin Patrick

AU - Erwin, Patricia J.

AU - Matteson, Eric Lawrence

PY - 2008/10/20

Y1 - 2008/10/20

N2 - Introduction: The purpose of the present study was to systematically review the effect of cyclophosphamide treatment on pulmonary function in patients with systemic sclerosis and interstitial lung disease. Methods: The primary outcomes were the mean change in forced vital capacity and in diffusing capacity for carbon monoxide after 12 months of therapy in patients treated with cyclophosphamide. Results: Three randomized clinical trials and six prospective observational studies were included for analysis. In the pooled analysis, the forced vital capacity and the diffusing capacity for carbon monoxide predicted values after 12 months of therapy were essentially unchanged, with mean changes of 2.83% (95% confidence interval = 0.35 to 5.31) and 4.56% (95% confidence interval = -0.21 to 9.33), respectively. Conclusions: Cyclophosphamide treatment in patients with systemic sclerosis-related interstitial lung disease does not result in clinically significant improvement of pulmonary function.

AB - Introduction: The purpose of the present study was to systematically review the effect of cyclophosphamide treatment on pulmonary function in patients with systemic sclerosis and interstitial lung disease. Methods: The primary outcomes were the mean change in forced vital capacity and in diffusing capacity for carbon monoxide after 12 months of therapy in patients treated with cyclophosphamide. Results: Three randomized clinical trials and six prospective observational studies were included for analysis. In the pooled analysis, the forced vital capacity and the diffusing capacity for carbon monoxide predicted values after 12 months of therapy were essentially unchanged, with mean changes of 2.83% (95% confidence interval = 0.35 to 5.31) and 4.56% (95% confidence interval = -0.21 to 9.33), respectively. Conclusions: Cyclophosphamide treatment in patients with systemic sclerosis-related interstitial lung disease does not result in clinically significant improvement of pulmonary function.

UR - http://www.scopus.com/inward/record.url?scp=55749093240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55749093240&partnerID=8YFLogxK

U2 - 10.1186/ar2534

DO - 10.1186/ar2534

M3 - Article

C2 - 18937831

AN - SCOPUS:55749093240

VL - 10

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 5

M1 - R124

ER -